<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increasing evidence that <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> originate from small populations of so-called <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> stem cells (<z:chebi fb="11" ids="17437,53115">CSCs</z:chebi>), capable of surviving conventional chemotherapies and regenerating the original <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, urges the development of novel <z:chebi fb="11" ids="17437,53115">CSC</z:chebi>-targeted treatments </plain></SENT>
<SENT sid="1" pm="."><plain>Screening of new anticancer compounds is conventionally conducted on established <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines, providing sufficient material for high-throughput studies </plain></SENT>
<SENT sid="2" pm="."><plain>Whether <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell lines might comprise <z:chebi fb="11" ids="17437,53115">CSC</z:chebi> populations resembling those of <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e>, however, remains highly debated </plain></SENT>
<SENT sid="3" pm="."><plain>We have analyzed the expression of defined phenotypic profiles, including CD133+, CD166+CD44+, and CD24+CD44+, reported as <z:chebi fb="11" ids="17437,53115">CSC</z:chebi>-specific in human primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), on a panel of 10 established <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines and evaluated their correlation with <z:chebi fb="11" ids="17437,53115">CSC</z:chebi> properties </plain></SENT>
<SENT sid="4" pm="."><plain>None of the putative <z:chebi fb="11" ids="17437,53115">CSC</z:chebi> phenotypes consistently correlated with stem cell-like features, including spheroid formation ability, clonogenicity, <z:chebi fb="1" ids="17478">aldehyde</z:chebi> dehydrogenase-1 activity, and side population phenotype </plain></SENT>
<SENT sid="5" pm="."><plain>Importantly, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells expressing putative <z:chebi fb="11" ids="17437,53115">CSC</z:chebi> markers did not exhibit increased survival when treated with chemotherapeutic drugs in vitro or display higher tumorigenicity in vivo </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, the expression of CD133 or the coexpression of CD166/CD44 or CD24/CD44 did not appear to reliably identify <z:chebi fb="11" ids="17437,53115">CSC</z:chebi> populations in established <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines </plain></SENT>
<SENT sid="7" pm="."><plain>Our findings question the suitability of cell lines for the screening of <z:chebi fb="11" ids="17437,53115">CSC</z:chebi>-specific therapies and underline the urgency of developing novel platforms for anticancer drug discovery </plain></SENT>
</text></document>